rs25487 — XRCC1 R399Q

Base excision repair scaffold protein that coordinates repair of oxidative DNA damage and single-strand breaks; the Gln variant reduces repair efficiency at the PARP-binding domain

See your personal result for XRCC1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

XRCC1 R399Q — Your DNA Damage Repair Coordinator

Every day, your DNA sustains tens of thousands of lesions from normal metabolism — oxidative hits from mitochondrial respiration, alkylation from reactive metabolites, and spontaneous depurination. The base excision repair (BER) pathway11 base excision repair (BER) pathway
The primary mechanism for repairing small, non-helix-distorting base lesions in DNA. BER handles oxidized bases (like 8-oxoguanine), deaminated bases, and single-strand breaks — the most common types of DNA damage. is the frontline defense against this constant assault, and XRCC122 XRCC1
X-Ray Repair Cross-Complementing group 1 — despite its name suggesting radiation repair, XRCC1 is primarily a scaffold protein for base excision repair of everyday oxidative DNA damage is its central coordinator. XRCC1 has no enzymatic activity of its own; instead, it serves as a molecular scaffold that physically recruits and organizes the enzymes needed at each step of the repair process.

The rs25487 variant (R399Q) changes arginine to glutamine at position 399, right in the BRCT1 domain33 BRCT1 domain
BRCA1 C-terminal domain 1 — a protein-protein interaction module found in many DNA repair proteins. In XRCC1, the BRCT1 domain mediates the critical interaction with PARP-1, the enzyme that detects single-strand breaks. that mediates the interaction with PARP-1. This single amino acid change subtly reduces the efficiency of the entire BER assembly, with consequences that become measurable at the population level — particularly when combined with environmental DNA-damaging exposures.

The Mechanism

XRCC1 functions as a multi-domain scaffold with distinct binding sites for each BER enzyme. PARP-144 PARP-1
Poly(ADP-ribose) polymerase 1 — the "damage sensor" that detects single-strand breaks and signals for repair by attaching poly(ADP-ribose) chains to nearby proteins, including itself first detects the strand break and synthesizes poly(ADP-ribose) chains that recruit XRCC1 to the damage site. XRCC1 then sequentially coordinates DNA polymerase beta55 DNA polymerase beta
The gap-filling polymerase that inserts the correct nucleotide after the damaged base has been removed, DNA ligase III66 DNA ligase III
Seals the remaining nick in the sugar-phosphate backbone to complete the repair, and polynucleotide kinase77 polynucleotide kinase
Processes damaged DNA termini so they can be properly joined.

The Arg399Gln substitution occurs within the BRCT1 domain responsible for PARP-1 binding. The glutamine residue alters the electrostatic properties of this interaction surface, reducing the affinity between XRCC1 and PARP-1. This does not abolish repair — it slows the kinetics of scaffold assembly. Under normal conditions, the delay may be inconsequential. Under high oxidative stress or heavy carcinogen exposure, the reduced repair throughput allows more DNA damage to persist through cell division, increasing mutagenesis.

Functional studies confirm the consequence: Lunn et al.88 Lunn et al.
Lunn RM et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res, 1999 found that individuals carrying the 399Gln allele had significantly higher levels of aflatoxin B1-DNA adducts and elevated frequencies of glycophorin A somatic mutations — both direct biomarkers of reduced DNA repair capacity in vivo.

The Evidence

Lung cancer. A meta-analysis of 8 studies in Chinese populations99 meta-analysis of 8 studies in Chinese populations
Zheng H et al. XRCC1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer, 2009 (2,861 cases, 2,783 controls) found the combined Arg/Gln+Gln/Gln genotype borderline significantly associated with lung cancer risk (OR 1.16, 95% CI 1.00-1.36). The gene-smoking interaction is biologically coherent: tobacco smoke generates massive oxidative DNA damage and bulky adducts, overwhelming BER capacity that is already reduced by the variant. A systematic review of XRCC1 polymorphism data1010 systematic review of XRCC1 polymorphism data
Ginsberg G et al. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res, 2011 found that Gln/Gln homozygotes have 3-4-fold diminished capacity to remove DNA adducts and oxidized DNA damage, providing a mechanistic basis for the observed gene-carcinogen exposure interactions.

Gastric cancer. A HuGE review and meta-analysis of 12 studies1111 HuGE review and meta-analysis of 12 studies
Xue H et al. XRCC1 genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis. Am J Epidemiol, 2011 found a pooled OR of 1.04 (95% CI 0.90-1.20) for the Arg399Gln variant and gastric cancer, with no statistically significant overall association. The interaction with Helicobacter pylori1212 Helicobacter pylori
A bacterium that colonizes the stomach lining, causing chronic inflammation and oxidative stress. H. pylori infection combined with impaired BER may compound gastric cancer risk. infection is suspected but not yet fully quantified in large studies.

Bladder cancer. A meta-analysis of 24 case-control studies1313 meta-analysis of 24 case-control studies
Yang D et al. Association of XRCC1 Arg399Gln polymorphism with bladder cancer susceptibility: a meta-analysis. Gene, 2014 found a modest association in heterozygote carriers (AG vs GG: OR 1.11, 95% CI 1.02-1.21), with stronger effects in non-Asian populations. Bladder epithelium is chronically exposed to urinary carcinogens and their metabolites, making efficient BER particularly important in this tissue.

Overall cancer risk. A meta-analysis of 38 case-control studies1414 meta-analysis of 38 case-control studies
Hu Z et al. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev, 2005 (11,957 cases, 14,174 controls) found no significant overall association for the Arg399Gln variant (Gln/Gln OR 1.01, 95% CI 0.90-1.14), with notable heterogeneity by cancer site. The effect sizes for individual cancer types are modest (OR approximately 1.0-1.2), consistent with a common variant that modestly shifts lifetime cancer probability in specific tissues rather than deterministically causing disease.

Practical Actions

The actionable insight from XRCC1 R399Q centers on supporting the BER pathway biochemically. PARP-1, the enzyme whose interaction with XRCC1 is impaired by this variant, consumes NAD+1515 NAD+
Nicotinamide adenine dinucleotide — an essential coenzyme that PARP-1 cleaves to generate the poly(ADP-ribose) chains used in damage signaling. Heavy DNA damage can deplete cellular NAD+ pools. as its substrate. Under conditions of high DNA damage, PARP-1 activity can substantially deplete cellular NAD+ reserves. For carriers of the 399Gln variant, where PARP-1 recruitment is already suboptimal, ensuring adequate NAD+ precursor availability becomes especially relevant.

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are direct NAD+ precursors that bypass the rate-limiting step in the salvage pathway. Supporting NAD+ levels ensures PARP-1 has sufficient substrate to generate the damage-signaling chains that recruit XRCC1 to repair sites.

Additionally, reducing the burden of oxidative DNA damage through targeted antioxidant strategies — particularly compounds shown to reduce 8-oxoguanine formation — can partially compensate for slower repair kinetics. Sulforaphane from cruciferous vegetables upregulates the Nrf2 pathway, which increases expression of multiple antioxidant and DNA repair enzymes.

Interactions

XRCC1 R399Q interacts with other DNA repair pathway variants. The most direct interaction is with rs1799782 (XRCC1 R194W), another variant in the same gene located in the linker region between the N-terminal and BRCT1 domains. Compound heterozygosity for both R399Q and R194W has been associated with further reduced repair capacity compared to either variant alone, though large studies quantifying the combined effect are limited.

Interaction with rs1799793 (ERCC2 D312N) is biologically plausible: ERCC2/XPD participates in nucleotide excision repair of bulky DNA adducts, a complementary pathway to BER. When both BER (via XRCC1) and NER (via ERCC2) are impaired, the overall DNA repair capacity is more substantially compromised. Several studies have reported elevated cancer risk when variant alleles at both loci co-occur.

The interaction with NBS1 rs1805794 (E185Q) follows similar logic — NBS1 participates in double-strand break sensing via the MRN complex. Reduced function in both single-strand (XRCC1) and double-strand (NBS1) repair pathways could compound genomic instability.

Nutrient Interactions

NAD+ increased_need
niacin increased_need

Genotype Interpretations

What each possible genotype means for this variant.

CC Full Repair Activity Normal

Normal XRCC1 scaffold function with efficient base excision repair

You carry two copies of the C allele (Arg/Arg), encoding the wild-type XRCC1 protein with arginine at position 399. Your BRCT1 domain has normal affinity for PARP-1, allowing efficient assembly of the base excision repair complex at DNA damage sites. About 40% of people of European descent share this genotype, though it is more common in African populations (approximately 76%).

CT Reduced Repair Activity Intermediate

One copy of the Gln399 variant — modestly reduced BER scaffold efficiency

The heterozygous state produces both Arg399 and Gln399 forms of XRCC1. The Gln399 protein has subtly reduced PARP-1 binding affinity in the BRCT1 domain, slowing the assembly of the BER repair complex. Under normal conditions, the wild-type copy provides sufficient scaffold function. The clinical effect becomes measurable primarily under conditions of heavy oxidative or carcinogenic stress — tobacco smoke exposure, chronic inflammation, or occupational carcinogen exposure.

Population studies show modest and inconsistent associations across cancer types. Meta-analyses find borderline lung cancer associations in Asian populations (combined variant genotypes OR ~1.16) and modest bladder cancer associations in heterozygotes (OR ~1.11 in non-Asian populations). Effect sizes are small and shift lifetime probability rather than determine outcomes.

TT Significantly Reduced Repair Reduced

Two copies of the Gln399 variant — meaningfully reduced BER scaffold efficiency

With both copies carrying Gln399, your entire XRCC1 pool has reduced PARP-1 binding affinity in the BRCT1 domain. Functional biomarker studies show that Gln/Gln carriers accumulate higher levels of DNA adducts (aflatoxin B1-DNA adducts) and somatic mutations (glycophorin A variants) compared to Arg/Arg carriers, confirming reduced in vivo DNA repair capacity.

The clinical impact is most evident under conditions of high DNA damage load. The gene-smoking interaction is the best documented: tobacco smoke generates both oxidative lesions and bulky adducts at rates that overwhelm BER capacity more quickly when the XRCC1 scaffold is impaired. Similar logic applies to chronic H. pylori gastritis (gastric cancer) and urinary carcinogen exposure (bladder cancer).

It is important to frame this proportionately: the effect sizes across published meta-analyses are modest (OR approximately 1.0-1.2 depending on cancer site), and this variant shifts lifetime probability rather than determining disease. Millions of Gln/Gln carriers live cancer-free lives. The variant becomes most relevant when combined with modifiable environmental exposures.